An interventional study of Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy. and Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone. in Overweight or Obesity and Chronic Low-back Pain, sponsored by Vrije Universiteit Brussel. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Obesity with a site in Belgium — 40 open to participants now, 56 under way, 22 of them phase 3. Obesity · Belgium.
Among the 133 studies in Obesity with a site in Belgium, this one is the 44th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2023, is one of 36 with no phase, reaches primary completion later than 32 of the 55 other live ones, and was the 94th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →40 of the 133 studies in Obesity with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Israel and 7 more countries
Ages 6–11
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–65
Novo Nordisk A/S · Sites in Belgium, United States, Bulgaria and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Belgium, United States, Argentina and 16 more countries
Ages 18+
Université Catholique de Louvain · Sites in Belgium
Ages 18–65
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2001; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 252 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 200 across the 97 interventional studies, 150 across the 35 observational. Of the 65 that completed or were terminated, 15 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 133 have an industry lead sponsor. The 10 most frequent:
Vrije Universiteit Brussel is the lead sponsor of 160 studies on the registry; 43 are open to participants now.
Vrije Universiteit Brussel has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Belgium that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07145671Universiteit AntwerpenThe COCCOS Study: a Transition Program for Young Persons With Chronic Conditions | 2026-12 |
| NCT05315752Centre Hospitalier Universitaire Saint PierreChanges in Body Fat and Morphologic Characteristics Associated With OSA Resolution After Bariatric Surgery | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 133 studies in Obesity with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic low back pain (CLBP) is the most expensive cause of workrelated disability: it causes the highest number of years lived with disability. The most severe and debilitated CLBP patients often have comorbidities such as overweight and obesity. Despite the growing body of scientific literature pointing towards the close interaction between overweight/obesity and CLBP, few treatment programs for people with CLBP nowadays take overweight into account. Therefore this study will examine the added value of a behavioral weight reduction program (changes in diet, behavior and physical exercise) to current best evidence rehabilitation (pain neuroscience education plus cognition-targeted exercise therapy) for overweight or obese people with CLBP. An international, multicenter randomized controlled trial comparing a behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy versus pain neuroscience education and cognition-targeted exercise therapy alone, will be conducted. The primary outcome is pain and the primary endpoint was chosen at 12 months follow-up; secondary outcomes include health care use and daily functioning (see detailed description of outcomes for an overview of all secondary outcomes). If the promising results of the proof of concept study are corroborated, the new intervention will have a high socio-economic impact, including an annual health care cost reduction of €66 million in Switzerland, and €60 million in Flanders, and is expected to increase life expectancy in the long term.
Rationale:
Chronic low back pain (CLBP) is the most common and important clinical, social, economic, and public health problem of all chronic pain disorders across the world. In addition to its high prevalence, CLBP is a severely disabling disorder characterized by tremendous personal and socioeconomic impact. Furthermore, it is the most common cause of work-related disability, generating long-term sick-leaves, and it causes the highest number of years lived with disability.
The most severe and debilitated CLBP patients often have comorbidities such as overweight and obesity. In fact, pain intensity and disability in people with CLBP show dose-responses to body mass index (BMI), waist circumference, percent fat and fat mass. Ample studies and several meta-analyses indeed confirm that overweight and obesity are associated with LBP, with overweight and obesity even being a risk factors for low back pain. Regarding socio-economic impact, overweight or obesity is not only related to LBP persistence, but also to higher rates of health care seeking for LBP. Obviously, people with CLBP who are overweight or obese, are likely to have more complex health needs requiring focus on lifestyle behavioral factors such as physical activity/exercise and diet.
CLBP is a complex disorder which is difficult to treat. Exercise therapy is an evidence-based treatment for CLBP both general exercises and cognition-targeted exercise therapy have shown beneficial effects on pain in patients with CLBP. Unfortunately, current treatments for CLBP apply a 'one-size-fits-all' approach and do not address comorbidities like obesity. This knowledge gap is now acknowledged internationally: overweight and obesity are increasingly recognized as a plausible therapeutic target for people with CLBP. Despite the growing body of scientific literature pointing towards the close interaction between overweight/obesity and CLBP few treatment programs for people with CLBP nowadays take overweight into account.
Few studies explored the added value of weight reduction to the management of people with CLBP. Yet, proof of concept for combining dietary changes with exercise therapy for patients with CLBP and comorbid overweight/obesity show promising results. Here we propose studying the added value of a behavioral weight reduction program (changes in diet, behavior, and physical exercise) to blended rehabilitation (PNE plus CTET) for overweight or obese people with CLBP. Both treatments are effective in their specific target population (i.e., behavioral weight reduction for overweight/obese people and PNE plus CTET for people with CLBP and normal BMI), but whether their combined approach is cumulative in overweight/obese people with CLBP is currently unknown and represents an important research priority.
Objectives:
The primary objective is to examine if a behavioral weight reduction program combined with Pain Neuroscience Education (PNE) and Cognition-Targeted Exercise Therapy (CTET) is superior to reduce pain at 12 months follow-up compared PNE and CTET alone, in overweight or obese people with CLBP.
Secondary objectives are to examine the effects of adding a behavioral weight reduction program combined with PNE and CTET, compared to PNE and CTET alone, on 1) other pain related outcomes (pain interference, pain distribution and pain beliefs), 2) on anthropometrics (body weight/composition, muscle thickness and fat distribution), 3) on energy balance related behavior (24h continuous activity monitoring, dietary intake and sleep) and finally 4) on health economics (heath care utilization, productivity loss and quality of life) at 12 months follow-up.
Interventions:
Both interventions (experimental and control) are organized equally: all participants will receive 18 treatment sessions over a 14-week period see table 2 for a detailed overview. Rather than practical, treatment arms will differ in content.
The control intervention will consist of a total of 18 treatment sessions distributed over 14 weeks. It comprises of only the chronic-pain-focused interventions: 3 sessions of PNE in the first 2 weeks \& secondly, 15 sessions of CTET in the remaining 12 weeks.
The experimental intervention will consist of a total of 18 treatment sessions distributed over 14 weeks. The first part will consist of chronic-pain-focused interventions: firstly, 3 sessions of PNE in the first 2 weeks \& secondly, 15 sessions of CTET in the remaining 12 weeks. The second part will consist of a more weight-reduction-focused intervention. The weight reduction intervention is a lifestyle approach that will be integrated in the CTET intervention, implying that grading daily physical activity and exercise levels will aim at reducing weight (i.e. together with a change in diet we aim at a caloric deficit of 500 to 700 kcal/day) and improving pain cognitions at the same time.
Study design:
Randomized controlled trial with follow-up assessments directly post-treatment (T1), 3 months post-treatment (T2), 6 months post-treatment (T3), 9 months post-treatment (T4) and 12 months post-treatment (T5).
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 252 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Vrije Universiteit Brussel is the lead sponsor of 160 studies on the registry; 43 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
Behavioral: Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
Behavioral: Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
14 weeks, 18 treatment sessions This includes: * 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms. * 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day.
Also known as: EXP (Experimental intervention)
14 weeks, 18 treatment sessions This includes: * 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms. * 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful.
Also known as: CON (Control intervention)
Brief Pain Inventory - Average pain Intensity
Since CLBP is a fluctuating condition, the question "please rate your pain by circling the one number that best describes your pain on the AVERAGE" is used as primary outcome measure to evaluate pain intensity. The answer to this question is formulated on an 11-point (i.e., 0-10, a decrease of 30% is considered as clinically significant) numeric rating scale (NRS). Higher scores indicate higher pain intensity.
Time frame: Change from baseline to 12 months post-intervention
Brief Pain Inventory - Pain intensity (Average, worst, least, now)
The BPI will also be used to assess pain intensity at other timepoints.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Brief Pain Inventory - Pain interference on functioning
The BPI also evaluates the impact of pain on functioning. The BPI measures how much pain interferes with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep on an 11-point NRS (ranging from 0-10). Higher scores indicate a bigger interference of pain with activities of daily life.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Pain distribution and pain extent by pain drawings
Extent of pain will be indicated by the participants making use of a digital pain drawing obtained using a digital tablet and commercially available sketching software
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Tampa Scale for Kinesiophobia (TSK)
The TSK contains questions about pain-related fear of movement, fear of (re)injury and fear avoidance behavior. The TSK results in a score ranging from 17 to 68, where higher scores indicate an increasing degree of kinesiophobia.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Fear Avoidance Belief Questionnaire
The fear avoidance belief questionnaire focuses on LBP patient's beliefs about how physical activity and work affect LBP (fear of pain caused by physical activity). This questionnaire results in a total score (ranging from 0 to 96) and two subscale scores: work subscale (ranges from 0 to 42) and physical activity subscale (score 0 to 24). Higher scores indicate more strongly held fear avoidance beliefs.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Body weight - Tanita
Body weight (kg) will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
BMI - Tanita
BMI will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Fat mass - Tanita
Fat mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Fat free mass - Tanita
Fat free mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Muscle mass - Tanita
Muscle mass will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Body Water - Tanita
Body water will be measured using TANITA MC-780SMA Bio-electrical Impedance Analyzer.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Waist-hip circumference
Measured using a Cescorf measuring tape,
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Regional body composition - portable ultrasound scanner
Subcutaneous adipose tissue thickness of the triceps, biceps, subscapular, iliac crest, supraspinal, abdominal and medial calf will be assessed. Additionally, muscle thickness of the multifidi will be assessed.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Accelerometry Fitbit
To objectively measure sedentary behavior, physical activity and sleep quantity/quality
Time frame: This outcome will be assessed at Baseline, directly post-treatment, and 12 months past-treatment
Sleep Quality - Pittsburg Sleep Quality Index
Questionnaire assessing Sleep Quality. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Dietary Intake
a 3 day food diary, 2 week days and 1 weekend day, will be used to analyse their dietary intake.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment and 12 months past-treatment
Health Economics - Medical Consumption Questionnaire
a generic instrument for measuring patient's total direct and indirect medical consumption. For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment
Health Economics - Productivity Cost Questionnaire
to obtain data regarding the indirect medical costs (e.g., the costs due to absenteeism or presenteeism). For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment
Health Economics - EuroQol EQ-5D-5L
to assess health profiles which will be transformed into utilities using the Flemish or German Tariffs respectively. For this type of questionnaire and the aspect it is measuring, we cannot refer to minimum or maximum values.
Time frame: This outcome will be assessed at Baseline, directly post-treatment, 3 months post-treatment, 6 months post-treatment, 9 months post-treatment and 12 months past-treatment
Plan to share: No — We do not plan to share any IPD
Started Apr 2023 (actual). Primary completion is estimated for Apr 2028, 60 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 60 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.